Market Cap | 1.03B | P/E | - | EPS this Y | 225.70% | Ern Qtrly Grth | - |
Income | 10.13M | Forward P/E | 12.12 | EPS next Y | -3.80% | 50D Avg Chg | 1.00% |
Sales | 449.39M | PEG | 5.13 | EPS past 5Y | -10.88% | 200D Avg Chg | 19.00% |
Dividend | N/A | Price/Book | 2.69 | EPS next 5Y | 2.20% | 52W High Chg | -6.00% |
Recommedations | 1.70 | Quick Ratio | 2.77 | Shares Outstanding | 20.43M | 52W Low Chg | 67.00% |
Insider Own | 12.14% | ROA | 3.11% | Shares Float | 14.78M | Beta | 0.89 |
Inst Own | 66.13% | ROE | 3.38% | Shares Shorted/Prior | 376.80K/415.40K | Price | 51.13 |
Gross Margin | 62.23% | Profit Margin | 2.98% | Avg. Volume | 142,772 | Target Price | 71.67 |
Oper. Margin | 11.68% | Earnings Date | Nov 8 | Volume | 67,516 | Change | 0.69% |
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations, including extended release and combination products. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Guggenheim | Buy | Oct 19, 23 |
Guggenheim | Buy | Sep 13, 23 |
HC Wainwright & Co. | Buy | Aug 22, 23 |
Truist Securities | Buy | Aug 21, 23 |
Guggenheim | Buy | Aug 10, 23 |
Guggenheim | Buy | Jul 27, 23 |
Truist Securities | Buy | Jul 21, 23 |
Guggenheim | Buy | May 9, 23 |
Truist Securities | Buy | May 9, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Shanmugam Muthusamy | HEAD OF R&D, COO-NOV.. HEAD OF R&D, COO-NOVITIUM OPS | Nov 17 | Sell | 51 | 13,000 | 663,000 | 982,620 | 11/20/23 |
Shanmugam Muthusamy | HEAD OF R&D, COO-NOV.. HEAD OF R&D, COO-NOVITIUM OPS | Nov 14 | Sell | 52.82 | 37,000 | 1,954,340 | 995,620 | 11/20/23 |
Davis Krista | SVP, CHIEF HR OFFICE.. SVP, CHIEF HR OFFICER | Nov 15 | Sell | 53.81 | 2,622 | 141,090 | 32,587 | 11/16/23 |
Gassert Chad | SVP - CORP. DEV. & S.. SVP - CORP. DEV. & STRATEGY | Oct 02 | Sell | 56.48 | 20,000 | 1,129,600 | 293,226 | 10/03/23 |
Shanmugam Muthusamy | HEAD OF R&D, COO-NOV.. HEAD OF R&D, COO-NOVITIUM OPS | Sep 15 | Sell | 61.89 | 50,000 | 3,094,500 | 1,082,620 | 09/19/23 |
Gassert Chad | SVP - CORP. DEV. & S.. SVP - CORP. DEV. & STRATEGY | Sep 01 | Sell | 64.70 | 20,000 | 1,294,000 | 313,226 | 09/05/23 |
MERIDIAN VENTURE PARTNERS II L... | 10% Owner 10% Owner | Aug 16 | Sell | 58.50 | 200,000 | 11,700,000 | 1,819,259 | 08/16/23 |
Shanmugam Muthusamy | HEAD OF R&D, COO-NOV.. HEAD OF R&D, COO-NOVITIUM OPS | Aug 14 | Sell | 61.38 | 50,000 | 3,069,000 | 1,182,620 | 08/16/23 |
Pera Antonio R | Director Director | Aug 14 | Sell | 60.37 | 3,000 | 181,110 | 33,627 | 08/15/23 |
Lalwani Nikhil | PRESIDENT & CEO PRESIDENT & CEO | Aug 11 | Option | 29 | 11,616 | 336,864 | 365,006 | 08/15/23 |
Lalwani Nikhil | PRESIDENT & CEO PRESIDENT & CEO | Aug 11 | Sell | 59.44 | 68,282 | 4,058,682 | 353,390 | 08/15/23 |
Gassert Chad | SVP - CORP. DEV. & S.. SVP - CORP. DEV. & STRATEGY | Aug 01 | Sell | 51.06 | 20,000 | 1,021,200 | 333,226 | 08/03/23 |
Shanmugam Muthusamy | HEAD OF R&D, COO-NOV.. HEAD OF R&D, COO-NOVITIUM OPS | Jul 19 | Sell | 51.85 | 23,469 | 1,216,868 | 1,232,620 | 07/21/23 |
Shanmugam Muthusamy | HEAD OF R&D, COO-NOV.. HEAD OF R&D, COO-NOVITIUM OPS | Jul 14 | Sell | 51.11 | 26,531 | 1,355,999 | 1,256,089 | 07/18/23 |
Shanmugam Muthusamy | HEAD OF R&D, COO-NOV.. HEAD OF R&D, COO-NOVITIUM OPS | Jun 20 | Sell | 51.69 | 50,000 | 2,584,500 | 1,282,620 | 06/23/23 |
Gassert Chad | SVP - CORP. DEV. & S.. SVP - CORP. DEV. & STRATEGY | Jun 22 | Sell | 51.32 | 20,000 | 1,026,400 | 373,226 | 06/23/23 |
Marken James G. | SVP OPS & PROD DEV SVP OPS & PROD DEV | Aug 12 | Sell | 37.42 | 18,066 | 676,030 | 117,642 | 08/16/22 |
Lalwani Nikhil | PRESIDENT & CEO PRESIDENT & CEO | Mar 21 | Buy | 27.6851 | 7,224 | 199,997 | 169,650 | 03/23/22 |
Walsh Patrick D | Director Director | Mar 21 | Buy | 27.7588 | 5,000 | 138,794 | 53,388 | 03/22/22 |
Gassert Chad | SVP - CORP. DEV. & S.. SVP - CORP. DEV. & STRATEGY | Mar 18 | Buy | 27.51 | 10,000 | 275,100 | 393,226 | 03/22/22 |
Shanmugam Muthusamy | HEAD OF R&D, COO-NOV.. HEAD OF R&D, COO-NOVITIUM OPS | Mar 17 | Buy | 27.65 | 10,000 | 276,500 | 5,000 | 03/21/22 |